We conclude that the downregulation of fibulin-1 and/or of decorin in AAD patients could be an alternative molecular mechanism—opposed to a mutation in fibrillin-1 as seen in patients suffering from Marfan syndrome—leading to the same or similar phenotype. The gene discussed is DCN; the disease is Marfan syndrome.